Enzinger, Peter C <br/><br/>
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  08 2016 
 - 2736-42 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2015.65.5092  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--drug therapy<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--adverse effects<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Camptothecin--administration & dosage<br/>Carcinoma, Squamous Cell--drug therapy<br/>Cetuximab--administration & dosage<br/>Cisplatin--administration & dosage<br/>Disease Progression<br/>Disease-Free Survival<br/>Epirubicin--administration & dosage<br/>Esophageal Neoplasms--drug therapy<br/>Esophagogastric Junction<br/>Female<br/>Fluorouracil--administration & dosage<br/>Humans<br/>Irinotecan<br/>Leucovorin--administration & dosage<br/>Male<br/>Middle Aged<br/>Organoplatinum Compounds--administration & dosage<br/>Survival Rate<br/>Time Factors<br/>Treatment Failure